ACRSライブシグナル | Getagraph.comで利益を最大化

買う 108052 min ago

@ $1.220

発行日: 15 2月 2024 @ 00:55

リターン: 0.00%

前回のシグナル: 2月 14 - 23:47

前回のシグナル: 売る

リターン: 0.00 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:46):

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States...

Stats
本日の出来高	129 165
平均出来高	1.08M
時価総額	86.94M
EPS	$-0.0200 ( 2024-02-29 )
次の収益日	( $-0.340 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.960
ATR14	$0.00700 (0.57%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Walker Neal	Buy	9 467	Common Stock
2024-04-01	Walker Neal	Sell	3 224	Common Stock
2024-04-01	Walker Neal	Sell	9 467	Restricted Stock Units
2024-03-01	Walker Neal	Buy	9 466	Common Stock
2024-03-01	Walker Neal	Sell	3 223	Common Stock

INSIDER POWER
77.37
Last 99 transactions
Buy: 2 297 521 \| Sell: 311 390

ボリューム相関

長: -0.15 (neutral)

短: -0.50 (weak negative)

Signal:(53.621) Neutral

Aclaris Therapeutics Inc 相関

10 最も正の相関
POET	0.958
AACG	0.946
GETVV	0.946
AVIR	0.946
NAKD	0.945
HLIO	0.944
IMPL	0.944
CRTO	0.944
HTCR	0.941
CMMB	0.94

10 最も負の相関
IDCC	-0.95
MPRA	-0.949
TZPSU	-0.947
CEG	-0.945
SLMBP	-0.945
STRA	-0.944
GALT	-0.944
CALB	-0.943
PRAA	-0.942
MEOH	-0.941

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Aclaris Therapeutics Inc 相関 - 通貨/商品

0.00
( neutral )

-0.08
( neutral )

0.00
( neutral )

Aclaris Therapeutics Inc 財務諸表

Annual	2023
収益:	$31.25M
総利益:	$13.17M (42.14 %)
EPS:	$-1.270

FY	2023
収益:	$31.25M
総利益:	$13.17M (42.14 %)
EPS:	$-1.270

FY	2022
収益:	$29.75M
総利益:	$17.79M (59.80 %)
EPS:	$-1.360

FY	2021
収益:	$6.76M
総利益:	$2.05M (30.29 %)
EPS:	$-2.14

Financial Reports:

No articles found.

Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.